Here are seven things to know about the suit:
1. MiMedx allografts were “suddenly and unexpectedly” removed from the 65IIA Federal Supply Schedule of the Veterans Administration in June 2013.
2. MiMedx challenged the action and within a few days the VA decided MiMedx allograft removal wasn’t warranted and they were full restored to FSS. The VA also sent an apology letter to MiMedx.
3. After filing a Freedom of Information Act request, MiMedx received information that Organogenesis provided “material misinformation” to the VA that caused the decision to remove MiMedx products.
4. The lawsuit alleges “Organogenesis engaged in malicious actions that tortuously interfered with MiMedx’s contractual relationship selling into the VA,” according to a MiMedx report.
5. MiMedx plans to pursue “any and all remedies” to address Organogenesis’s actions.
6. The suit also inserts unjust enrichment.
7. The lawsuit was filed in the United States District Court for the Northern District of Georgia and damages sought were not specified.
More articles on orthopedic devices:
Is the Zimmer-Biomet acquisition unraveling? 5 quick updates
8 things to know about Johnson & Johnson stock—A good investment?
FDA draft guidance for human cell tissue manipulation—MiMedx responds
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.